References
1. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020 ;
383(23): 2255-73.
2. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al.
Immunopathogenesis and treatment of cytokine storm in COVID-19.
Theranostics 2021 ; 11(1): 316-29.
3. Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E,
Tomelleri A, Dagna L. Repurposing of biologic and targeted synthetic
anti-rheumatic drugs in COVID-19 and hyper-Inflammation: A comprehensive
review of available and emerging evidence at the peak of the pandemic.
Front Pharmacol 2020 ; 11: 598308.
4. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.
Dexamethasone in hospitalized patients with Covid-19. N Engl J Med2021 ; 384(8): 693-704.
5. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud
P. Effect of tocilizumab vs usual care in adults hospitalized with
COVID-19 and moderate or severe pneumonia: A randomized clinical trial.
JAMA Intern Med 2021 ; 181(1): 32-40.
6. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L,
Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with
Covid-19. N Engl J Med 2020 ; 383(24): 2333-44.
7. Horby PW, Campbell M, Staplin N, Brightling CE, Sarkar R, Thomas K,
et al. Tocilizumab in patients admitted to hospital with COVID-19
(RECOVERY): preliminary results of a randomised, controlled, open-label,
platform trial. medRxiv preprint doi:
https://doi.org/10.1101/2021.02.11.21249258.
8. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN.
Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020 ;
80(13): 1267-92.
9. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et
al. Baricitinib as potential treatment for 2019-nCoV acute respiratory
disease. Lancet 2020 ; 395(10223): e30-e1.
10. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan
V, et al. Baricitinib plus remdesivir for hospitalized adults with
Covid-19. N Engl J Med 2021 ; 384(9): 795-807.
11. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO,
et al; STOP-COVID Trial Investigators. Tofacitinib in patients
hospitalized with Covid-19 pneumonia. N Engl J Med. 2021 Jun 16. doi:
10.1056/NEJMoa2101643. Epub ahead of print.
12. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford
H, Stöger L, Beenen L, et al. CO-RADS: A categorical CT assessment
scheme for patients suspected of having COVID-19 definition and
evaluation. Radiology 2020 ; 296(2): E97-E104.
13. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs2017 ; 77(18): 1987-2001.
14. Moiseev S, Avdeev S, Brovko M, Bulanov N, Tao E, Fomin V. Outcomes
of intensive care unit patients with COVID-19: a nationwide analysis in
Russia. Anaesthesia 2021 ; 76 Suppl 3: 11-2.